Asia-Pacific Emerges as a Core Hub for Life Science Innovations

Growing Significance of Asia-Pacific

During the recent Asia-Pacific Conference of German Business held in Seoul, Shashank Deshpande, the Chairman of the Board of Managing Directors at Boehringer Ingelheim, emphasized the increasing importance of the Asia-Pacific region in global life science innovation.

Boehringer Ingelheim has established a strong foundation in Japan, expanded its presence in China, and is building a vast network of collaborations throughout Asia-Pacific. The company currently manages over 200 clinical trials in the region while partnering with around 160 institutions.

Commitment to Life Science R&D

As Boehringer Ingelheim celebrates 50 years of its operations in Korea, the company reaffirms its dedication to research and development in the life sciences sector. Deshpande noted, “It is crucial to have predictable and science-friendly policy frameworks that encourage investment to enhance access to new health products, both for humans and animals.”

Amidst rising global competition for talent and investment, he remarked, “Asia-Pacific is rapidly becoming a key player in life science innovation.” By leveraging scientific expertise from Europe, the innovative environment of the United States, and the burgeoning R&D capabilities in Asia-Pacific, Boehringer aims to enhance its innovation potential—including integrating technologies from around the world.

Collaborations Across the Region

Boehringer Ingelheim's partnerships across Asia-Pacific encompass the entire journey from discovery to patient access. In 2025, the company executed over 200 clinical studies with more than 160 academic institutions across several countries, including Malaysia, the Philippines, Thailand, Japan, Korea, Australia, and New Zealand.

Its programs targeting chronic kidney disease and heart failure have successfully screened over 72,000 individuals, with local governments now expanding these initiatives. Additionally, the